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Doxorubicin (DX) is a chemotherapeutic drug that is used in clinical practice that
promotes deleterious side effects in non-tumor tissues such as adipose tissue. We
showed that DX leads to extensive damage in adipose tissue via a disruption in
5′-adenosine monophosphate-activated protein kinase (AMPK) and PPAR-gamma
signaling. Thus, we investigated whether co-treatment with the biguanide drug
metformin (MET) could prevent the side effects of DX through the activation of AMPK
in adipose tissue. The goal of the present study was to verify the effects of DX and
adjuvant MET treatment in subcutaneous adipose tissue (SAT) and to determine whether
MET could protect against chemotherapy-induced side effects. C57/BL6 mice received
DX hydrochloride (2.5 mg/kg) intraperitoneally 2 times per week for 2 weeks (DX),
concomitantly or not, with MET administration (300 mg/kg oral daily) (DX + MET). The
control group (CTRL) was pair-fed according to the food consumption of the DX group.
After euthanasia, adipose tissue fat pads were collected, and SAT was extracted so that
adipocytes could be isolated. Glucose uptake was then measured, and histological,
gene, and protein analyses were performed. One-way analysis of variance was also
performed, and significance was set to 5%. DX reduced retroperitoneal fat mass
and epididymal pads and decreased glycemia. In cultured primary subcutaneous
adipocytes, mice in the DX group had lower glucose uptake when stimulated with insulin
compared with mice in the CTRL group. Adipocytes in the DX group exhibited a reduced
area, perimeter, and diameter; decreased adiponectin secretion; and decreased fatty
acid synthase gene expression. SAT from MET-treated mice also showed a reduction in
collagen deposition. Treatment with MET prevented fibrosis and restored glucose uptake
in SAT after insulin stimulation, yet the drug was unable to prevent other side effects of
DX such as tissue loss and inflammatory response.
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INTRODUCTION
Doxorubicin is a chemotherapeutic belonging to the
anthracycline family that is highly effective in the treatment of
various adult and pediatric cancers such as lymphoma, solid
tumors, leukemia, and prostate and breast cancer (Sun et al.,
2016). Besides its efficacy, doxorubicin treatment decreases
quality of life because of its side effects including vomiting,
diarrhea, bleeding, extreme fatigue, discomfort, and anorexia,
which contribute to patient debilitation (Gorselink et al., 2006;
Hydock et al., 2011). Nevertheless, doxorubicin is known to
promote severe toxic effects in non-tumor tissues; cardiotoxicity
is well described in the literature (Benjamin et al., 1974; Hydock
et al., 2011) as are nephrotoxicity (Singla et al., 2014) and
hepatotoxicity (Gorselink et al., 2006; Ayla et al., 2011).
Although many researchers have demonstrated the toxic
effects of doxorubicin on cardiac muscle, few studies have
investigated the side effects of doxorubicin on adipose tissue. The
loss of adipose tissue and skeletal muscle after chemotherapy
are associated with a worse prognosis and a reduction in
quality of life (Rutten et al., 2016) and can lead to metabolic
and physiological disturbances. White adipose tissue is an
endocrine organ that secretes a variety of adipokines that
promotes cross-talk within diverse organs (e.g., heart, muscle,
and bone marrow). Adipokines are tightly associated with energy
balance (Argilés et al., 2005; Ghadge et al., 2014). For example,
adiponectin regulates lipid and glucose metabolism (Smitka
and Marešová, 2015), whereas leptin modulates ingestion and
energy expenditure (Szewczyk-Golec et al., 2015). Therefore,
the accelerated loss of adipose mass can lead to disturbances
in whole-body inflammatory and metabolic responses in cancer
patients. Our group showed that a single dose of doxorubicin
(15 mg/kg body weight) causes rapid loss of adipose mass (72 h)
together with an imbalance in adipokines (Biondo et al., 2016).
In response to injury, for the repair of tissue damage,
healing generally begins with local inflammation followed by
tissue remodeling through the alteration of extracellular matrix
components (Rockey et al., 2015). When a change in fat mass
occurs, adipose tissue also undergoes structural remodeling.
Excessive accumulation of fibrous connective tissue modifies the
function of adipose tissue (Rockey et al., 2015; Chabot et al.,
2017). High deposition of collagen, a major protein component
of the extracellular matrix, is often associated with fibrosis
(Divoux and Clément, 2011). In obesity, there is marked fibrosis
of subcutaneous adipose tissue (SAT) (Divoux and Clément,
2011; Choe et al., 2016), but few studies have evaluated fibrosis
associated with the loss of adipose tissue mass (Chabot et al.,
2017). It is known that hospitalized cancer patients exhibit
adipose tissue loss as a result of cancer-related cachexia (Argilés
et al., 2015) and fibrosis.
Therefore, co-therapies, which may reduce the toxic effects
of doxorubicin in white adipose tissue, can improve treatment
efficacy and help to ameliorate the quality of life during
treatment. We showed that doxorubicin decreased the activity
of the two primary metabolic pathways of adipose tissue: the
adenosine monophosphate-activated protein kinase (AMPK)
and PPAR-gamma pathways. These alterations can lead to
a disruption in metabolic reprogramming in adipose tissue.
Metformin (MET) is a hypoglycemic drug that acts through
AMPK activation and functions by limiting the synthesis of lipids
and glucose and by inhibiting complex 1 of the electron transport
chain during cellular respiration (Hawley et al., 2010; Viollet et al.,
2012). Many studies demonstrated efficient results with this drug
as a cancer treatment in both experimental and clinical practices
(Hosono et al., 2010; Landman et al., 2010; Hadad et al., 2015;
Kelleni et al., 2015) and have shown that MET co-treatment is
efficacious against cancer. Regarding the cardiotoxicity induced
by doxorubicin, it is known that MET treatment decreases the
expression of proinflammatory enzymes (Kelleni et al., 2015),
which induces AMPK signaling (Kobashigawa et al., 2014).
Moreover, with respect to adipose tissue, MET induces the AMPK
and PPAR signaling pathways and mitigates SAT fibrosis in older
humans (Kulkarni et al., 2018).
Thus, the aim of this study was to verify the effects of
doxorubicin and adjuvant MET treatment on SAT and to
determine whether MET could mitigate the side effects of
doxorubicin.
MATERIALS AND METHODS
Animals
The Experimental Research Committee of the University of São
Paulo approved all procedures for the care of the animals used
in this study. All experiments were performed in accordance
with the approved guidelines of the ICB-USP Animal Ethics
Committee (registered under n◦5, fls 15, book 03 of this
Institute).
In all, 36 male C57/BL6 mice approximately 8 weeks of age
(weighing 19–26 g) were obtained from the Biomedical Sciences
Institute of the University of São Paulo and were housed 2 or 3
per cage in an animal room under a 12:12 h light–dark cycle.
Mice were randomly divided into three groups: the control
group (CTRL); the doxorubicin group (DX), in which mice were
injected with doxorubicin hydrochloride at a dose of 2.5 mg/kg
of body weight intraperitoneally (i.p.) twice a week for 2 weeks
with (Eurofarma Laboratory, Campinas, São Paulo, Brazil); the
doxorubicin and MET group (DX + MET), in which mice
received doxorubicin i.p. and daily MET (Sigma-Aldrich, St.
Louis, MO, United States) orally at a dose of 300 mg/kg of body
weight. After the acclimation period, mice received a total of
10 mg/kg of doxorubicin, whereas the CTRL animals received an
equal volume of saline (Figure 1).
The mice received food (chow pellet diet, Nuvilab CR1,
Nuvital S/A, Colombo, Paraná, Brazil) and water. CTRL mice
were pair-fed in accordance with the food consumption of the
DX group; the food intake was equivalent among the groups to
avoid any effects of differences in total calorie intake. Food intake
and body weight were assessed every 2 and 3–4 days, respectively.
After MET gavage, the health and well-being of the animals were
monitored daily.
A total of 24 h after the last dose of MET, the mice were
euthanized by decapitation, and SAT was removed, weighed,
flash-frozen in liquid nitrogen, and stored at −80◦C. Blood was
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FIGURE 1 | Experimental protocol design.
drawn and centrifuged, and the serum was removed and kept
frozen at−80◦C for further analysis.
Adipocyte Isolation
The subcutaneous fat pad was dissociated in Dulbecco’s
Modified Eagle Medium (pH 7.4) (Sigma-Aldrich, St. Louis, MO,
United States) supplemented with HEPES (20 mM), sodium
pyruvate (2 mM), bovine serum albumin (BSA, 1%), and
collagenase type II (1 mg/mL) in an orbital bath shaker at 37◦C
for 20 min. Isolated adipocytes were filtered and washed three
times in the same buffer without collagenase. The adipocytes were
observed under an optical microscope (×100 magnification)
with an attached camera (Moticam 1000; Motic, Richmond, BC,
Canada).
2-Deoxy-D-Glucose (2-DG) Uptake
Primary subcutaneous adipocytes (106 cells/mL) were washed
in PBS and incubated with or without insulin (100 nmol/L) in
buffer containing 140 mM NaCl, 20 mM HEPES, 5 mM KCl,
2.5 mM MgSO4, 1 mM CaCl2, and 1% BSA (pH 7.4) for 20 min
at 37◦C. Subsequently, 2-deoxy-D-[3H]-glucose (0.4 mmol/L,
1850 Bq/tube or well) (Amersham Bioscience, United Kingdom)
was added, and the reaction was allowed to occur for exactly
3 min. The reaction was interrupted by the addition of 250 µL
ice-cold phloretin (0.3 mmol/L in Earle’s salts, 10 mM HEPES, 1%
BSA, and 0.05% DMSO). The primary adipocytes and 200 µL of
this final mixture were layered with 200 µL of silicone oil (density
of 0.963 mg/mL) in microfuge tubes and were centrifuged for 10 s
at 11,000g. The cell pellet on top of the oil layer was collected
and transferred to vials containing the scintillation cocktail
for radioactivity measurement using a Beta counter (450 LSC,
Counter Beta, Trilux, Perkin Elmer). The results were normalized
by diameter of the primary adipocytes and expressed as pmol
per cm2.
Subcutaneous Adipose Tissue Analysis:
Adiponectin, IL-4, IL-8, IL-12, IFNg, and
MCP-1
Frozen tissues (0.1 g) were homogenized in RIPA buffer (0.625%
Nonidet P-40, 0.625% sodium deoxycholate, 6.25 mM sodium
phosphate, and 1 M methylene-diaminetetraacetic acid at pH
7.4) containing 10 µg/mL of protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, United States). Homogenates were
centrifuged, the supernatant was recovered, and the protein
concentration was determined using a Bradford assay (Bio-
Rad, Hercules, CA, United States) with BSA as a reference.
The quantitative assessment of adiponectin; interleukin (IL)-
4, IL-8, and IL-12; interferon gamma (IFNg); and monocyte
chemoattractant protein 1 (MCP-1) in SAT was performed by
DuoSet Enzyme-Linked Immunosorbent Assay (DuoSet ELISA,
R&D Systems, Minneapolis, MN, United States).
Serum Analysis: Adiponectin, Leptin, and
Lipopolysaccharides
The quantitative assessment of adiponectin and leptin in the
serum was performed by ELISA (DuoSet ELISA, R&D Systems,
Minneapolis, MN, United States). Lipopolysaccharides (LPS)
were assessed by a QCL-1000 kit (Lonza, ref. 50-647U e 50-648U,
Walkersville, MD, United States).
Lipid Profile and Glucose Level
Serum levels of total cholesterol and triacylglycerol as well as
glycemia were determined by enzymatic methods (Labtest, Lagoa
Santa, Minas Gerais, Brazil). A colorimetric method assay was
employed for the quantitative determination of non-esterified
fatty acids in the serum (NEFA-HR, Wako, Mountain View, CA,
United States).
Histological Analyses
Small fragments of SAT were fixed in paraformaldehyde (10%),
embedded in paraffin, and serially cross-sectioned into 5-µm-
thick sections. The sections were stained with hematoxylin and
eosin (H&E) for morphological analyses, and Picro Sirius Red for
the detection of fibrosis. The 40× digital images were captured
using an optical microscope with an attached AxioCamm HRC
(Carl Zeiss, Andrade Gutierrez, Brazil). Quantification of the
adipocyte area, perimeter, and diameter was performed using
the 40× digital images of five independent sections obtained
from each mouse. Fibrotic areas were expressed as a percentage
compared with the total amount of tissue within the images.
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Quantitative Real-Time PCR
Total RNA was extracted from SAT with TRIzol (Invitrogen
Life Technologies, Carlsbad, CA, United States) and reverse
transcribed to cDNA using a High-Capacity cDNA kit (Applied
Biosystems, Warrington, United Kingdom). Expression of genes
related to glucose and lipid metabolism was evaluated by real-
time PCR using a Rotor-Gene Q cycler (Qiagen) and SYBR Green
as the fluorescent dye. Quantification of gene expression was
performed with RPL-19 gene as a control. The primer sequences
are shown in Table 1.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
statistics software package version 5.0 for Windows (GraphPad
Software, San Diego, CA, United States). The data are expressed
as means ± SD. Data were analyzed using the one-way analysis
of variance (ANOVA) test with Bonferroni’s post hoc test. Values
of p < 0.05∗, p < 0.01∗∗, p < 0.001∗∗∗, and p < 0.0001∗∗∗∗ were
considered statistically significant.
Although each treatment group consisted of 12 mice, the
amount of adipose tissue obtained from each individual was not
sufficient to perform all experiments on all the mice. For this
reason, some tests were performed on adipose tissue from a
smaller subgroup as indicated in the figure captions.
RESULTS
Treatment for 2 weeks with doxorubicin and MET did
not change the body weight or food ingestion of the
mice (Figures 2A,B). However, doxorubicin treatment
resulted in a reduction of subcutaneous, retroperitoneal,
and epididymal adipose tissues depots (Figures 3A–C). MET
treatment was not efficient in the prevention of adipose tissue
loss.
In parallel with the decline in adipose tissue mass, doxorubicin
promoted a reduction in area (Figure 4B), diameter (Figure 4C),
and perimeter (Figure 4D) of adipocytes, that were shown in
histological images (Figure 4A). These parameters were not
restored by MET. Doxorubicin also reduced gene expression of
Fas (Figure 4E), which is an essential enzyme for lipogenesis,
but DX did not affect the mRNA expression of Acc and Cebpα
(Figures 4F,G).
Doxorubicin treatment led to a reduction in adiponectin in the
SAT and in the serum (Figures 5A–C). No changes were observed
TABLE 1 | Primer sequences.
Gene 5′-Forward Primer-3′ 5′-Reverse Primer-3′
RPL-19 CAATGCCAACTCCCGTCA GTGTTTTTCCGGCAACGAG
Fas GATTCGGTGTATCCTGCTGTC CATGCTTTAGCACCTGCTGT
Acc CCAGCAGATTGCCAACATC ACTTCGGTACCTCTGCACCA
Cebp TAGGTTTCTGGGCTTTGTGG GATGGATCGATTGTGCTTCA
Oct-1 CCTGAAGATGATGTGCCTTG ATCAGGATGAGGGTGTGCTT
Col6a3 GCTGCGGAATCACTTTGTGC CACCTTGACACCTTTCTGGGT
Fibronectin-1 ATGTGGACCCCTCCTGATAGT GCCCAGTGATTTCAGCAAAGG
in the serum levels of leptin, triacylglycerol, free fatty acids,
total cholesterol, and endotoxin (Figures 6A–D, respectively).
Co-therapy with MET did not prevent alterations in the levels of
adipokines, changes in the lipid profile, or changes in endotoxin
concentration.
Doxorubicin reduced glycemia (Figure 7A) and glucose
uptake by primary adipocytes isolated from SAT under basal
conditions as well as in an insulin stimulated-state (Figures 7B,C,
respectively).
No drug effect was observed with respect to IL-4, IL-8, IL-12,
IFNg, and MCP-1 concentrations (Figures 8A–E). In addition to
the lack of statistical significance, these data suggest an extensive
disruption of adipose tissue homeostasis by the chemotherapy
drug DX and indicate that MET treatment did not prevent these
effects.
Finally, histological images showed that doxorubicin
increased fibrosis in SAT and that MET treatment was efficient
in preventing of this process (Figures 9A,B). Beyond that, the
combined effect of the drugs elevated Col6a3 gene expression
(Figures 9B,C), and doxorubicin augmented fibronectin
expression in both treatment groups (Figures 9C,D).
DISCUSSION
Doxorubicin administration is an effective treatment for several
types of cancer and primarily functions through the promotion of
cellular apoptosis (Rochette et al., 2015). However, this therapy
has highly undesired side effects including, but not limited to,
widely reported cardiotoxicity (Benjamin et al., 1974), DX also
disrupts glucose and lipid metabolism and affects whole-body
homeostasis (Biondo et al., 2016; De Lima Junior et al., 2016;
Heart et al., 2016). We demonstrated that doxorubicin treatment
caused a reduction in glucose uptake after insulin stimulation and
caused marked fibrosis in SAT. Both side effects were partially
counter-regulated by the co-administration of MET. However,
MET treatment was unable to prevent adipose tissue atrophy and
a reduction in adipokine production. Therefore, MET treatment
may be employed for the attenuation of doxorubicin-induced
side effects in SAT.
By itself, cancer leads to loss of adipose tissue mass, and
chemotherapy only exacerbates this loss (Ebadi and Mazurak,
2014; Vergoni et al., 2016). Decrease in adipose mass contributes
to a worse prognosis in cancer patients and is reported in
some metabolic disorders such as cachexia and lipodystrophy
(Ebadi and Mazurak, 2015). Our results showed a decrease in
adipose tissue mass in different anatomical sites (retroperitoneal,
subcutaneous, and epididymal) after doxorubicin treatment. In
addition to the finding that body weight was maintained during
the 2 weeks of treatment in all groups, the loss of adipose tissue
mass was very significant in both the DX and the DX + MET
groups. Because anorexia is a side effect of doxorubicin treatment,
our control group was pair-fed according to the treatment groups.
The weight of other organs and tissues analyzed (data not shown),
such as muscle and liver, did not change. This way, the mice
among the three groups have approximately the same body
weight as a result of isoenergetic intake. In addition, the area,
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FIGURE 2 | Body weight (A) and food consumption (B): mice were injected with doxorubicin hydrochloride (DX) or saline (CTRL) i.p. twice a week for 2 weeks; a
subset also received a daily oral gavage of metformin (DX + MET). Data are presented as means (n = 11). The groups were compared using one-way ANOVA
followed by Bonferroni’s post hoc tests.
FIGURE 3 | Weight of subcutaneous AT (A), retroperitoneal AT (B), and epididymal AT (C): mice were injected with doxorubicin hydrochloride (DX) or saline (CTRL)
i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of metformin (DX + MET). Data are presented as means ± SD (n = 11). The groups were
compared using one-way ANOVA followed by Bonferroni’s post hoc tests ∗∗∗p ≤ 0.001 and ∗∗∗∗p ≤ 0.0001.
FIGURE 4 | H&E staining (A) and the histological parameters of area (B), diameter (C), and perimeter of adipocytes (D). Gene expression of acetyl coA carboxylase
(Acc) (E), fatty acid synthase (Fas) (F), and CCAAT/enhancer-binding protein alpha (Cebpα) (G) in subcutaneous adipose tissue: mice were injected with doxorubicin
hydrochloride (DX) or saline (CTRL) i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of metformin (DX + MET). Data are presented as
means ± SD (n = 5). The groups were compared using one-way ANOVA followed by Bonferroni’s post hoc tests ∗p < 0.05, ∗∗p < 0.005, and ∗∗∗p < 0.001.
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FIGURE 5 | Serum adiponectin (A), subcutaneous AT adiponectin (B), and serum leptin (C): mice were injected with doxorubicin hydrochloride (DX) or saline (CTRL)
i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of metformin (DX + MET). Data are presented as means ± SD (n = 4–5). The groups were
compared using one-way ANOVA followed by Bonferroni’s post hoc tests ∗p ≤ 0.05 and ∗∗p ≤ 0.005.
FIGURE 6 | Triacylglycerol (A), free fatty acids (B), total cholesterol (C), and LPS (D) in the serum: mice were injected with doxorubicin hydrochloride (DX) or saline
(CTRL) i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of metformin (DX + MET). Data are presented as means ± SD (n = 6–7). The groups
were compared using one-way ANOVA followed by Bonferroni’s post hoc tests.
FIGURE 7 | 2-DG uptake in adipocytes extracted from the subcutaneous AT under basal conditions (A) and when stimulated by insulin (B), and serum glucose level
(C): mice were injected with doxorubicin hydrochloride (DX) or saline (CTRL) i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of metformin
(DX + MET). Data are presented as means ± SD. n = 3–5 (A,B) n = 6 (C). The groups were compared using one-way ANOVA followed by Bonferroni posttests
∗∗p ≤ 0.005.
diameter, and perimeter of adipocytes from SAT were reduced by
doxorubicin.
In accordance with the decline in adipose tissue mass and
adipocyte dimensions, doxorubicin reduced the expression of
the Fas gene; this gene encodes a key enzyme in the lipogenesis
process, which is essential for the maintenance of adipose
tissue mass. Together, these results showed an inhibition of
SAT anabolic pathways (Brunengraber et al., 2003). Our group
obtained similar findings in rats treated with a unique dose of
doxorubicin (15 mg/kg body weight) (Biondo et al., 2016).
The endocrine function of adipose tissue was impaired,
whereas the doxorubicin treatment caused reduction in
adiponectin and total adiponectin in SAT. Low adiponectin
is associated with the downregulation of PPAR-gamma gene
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FIGURE 8 | IL-4 (A), IL-8 (B), IL-12 (C), interferon-gamma (D), and MCP-1 in subcutaneous adipose tissue (E): mice were injected with doxorubicin hydrochloride
(DX) or saline (CTRL) i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of metformin (DX + MET). Data are presented as means ± SD (n = 4).
The groups were compared using one-way ANOVA followed by Bonferroni’s post hoc tests.
FIGURE 9 | Picro Sirius Red staining (A), collagen quantification (B), gene expression of collagen 6 alpha 3 (Col6a3) (C), and fibronectin-1 (D) in subcutaneous
adipose tissue: mice were injected with doxorubicin hydrochloride (DX) or saline (CTRL) i.p. twice a week for 2 weeks, and a subset received a daily oral gavage of
metformin (DX + MET). Data are presented as means ± SD (n = 4). The yellow arrow indicates fibrosis process. The groups were compared using one-way ANOVA
followed by Bonferroni’s post hoc tests ∗p ≤ 0.05 and ∗∗p ≤ 0.005.
expression; both effects were induced by doxorubicin and
were shown in our previous study (Biondo et al., 2016). This
impairment in adipokine homeostasis could induce changes
in the physiological function of adipose tissue, including lipid
mobilization factors and local and systemic inflammation.
Treatment with MET induced the activation of PPARs in SAT
of older adults (Kulkarni et al., 2018). However, in our study,
MET was not able to restore adiponectin or Fas expression in
SAT, which indicates that PPAR activity was not restored by
co-administration of MET.
In general, adiponectin concentration is inversely associated
with an insulin-resistant state (Weyer et al., 2001) through the
AMPK pathway. MET is a potent AMPK activator drug in
adipose tissue and promotes GLUT-4 translocation and, in this
way, sensitizes cells to insulin (Lee et al., 2012). Our results
showed that MET co-treatment restored stimulated glucose
uptake by isolated adipocytes.
Disturbances promoted by doxorubicin administration could
lead to higher expression of chemokines in adipose tissue and
adipocytes (Vergoni et al., 2016). In contrast to these data,
we did not observe any increase in inflammatory markers or
chemoattractants of immune system cells in adipose tissue. It is
probable that the administration of doxorubicin over 2 weeks
was considered a chronic protocol that leads to a severe loss of
adipose tissue, which could impair the secretion of chemokines
and adipokines.
LPS is a glycolipid found in membrane of Gram-negative
bacteria. In gut, it can increases the paracellular permeability,
allowing the entrance of bacteria through gut epithelial cells to
the serum. LPS activates toll-like receptor 4 in cells of immune
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system, such as macrophages and dendritic cells, and triggers
inflammatory responses such as production of cytokines (Bein
et al., 2017). The doxorubicin and MET did not change endotoxin
concentrations and inflammatory markers.
Doxorubicin-induced fibrosis and inflammation have been
described in different organs, such as the liver, heart, and kidney
(Henninger et al., 2012; Ma et al., 2012; Szalay et al., 2015).
Generally, both fibrosis and inflammation were found after a
single high dose of doxorubicin (10 mg/kg body weight), which
led to a reduction in survival rate (Krysko et al., 2011; Henninger
et al., 2012; Ma et al., 2012). Our findings showed that low doses
of doxorubicin (2.5 mg/kg body weight), as part of a chronic
administration protocol (twice per week for 14 days), exacerbated
fibrosis in the stromal vascular fraction and reduced the number
of adipocytes. The co-administration of MET could reduce the
extent of fibrosis and restore cell area. This anti-fibrotic effect
of MET is well described in the literature in several tissue types
(Lu et al., 2015; Doyle et al., 2016; Mummidi et al., 2016; Shen
et al., 2016) including in adipose tissue of obese mice (Luo et al.,
2016).
This increase in fibrosis leads to complications in adipose
tissue such as high extracellular matrix rigidity and reduced
expandability. It also induces ectopic lipid deposition, which
leads to insulin resistance and impairment of metabolic pathways
(Xie et al., 2017).
Unexpectedly, the mRNA expression of Col6a3 was increased
in the group treated with MET. This result was contradictory
to the mitigation of fibrosis found in the DX + MET group.
Moreover, fibronectin mRNA was increased in both the DX
and the DX + MET groups. Elevation of fibronectin and
Col6a3 gene expression did not reveal the pathways that lead
to fibrosis. We hypothesize that MET impairs the translation
of these genes or that it augments collagen degradation, which
would reduce collagen deposition. Recently, Kulkarni et al.
(2018) showed that MET regulates the expression of genes that
function in extracellular matrix organization and genes related
to collagen chain trimerization in SAT of older humans. Thus,
the molecular mechanism by which MET reduces fibrosis in SAT
after doxorubicin treatment is still unclear, but the physiological
and clinical relevance of this finding may improve the quality of
life of patients.
Doxorubicin leads to cellular apoptosis in adipose tissue via
the induction of DNA damage, as DX inhibits topoisomerase 2,
which causes double-strand breaks in DNA, and consequently,
cell death (Rochette et al., 2015). Additionally, researchers
have used this medicine in mice and in cultured cell lines
to induce apoptosis in adipose-derived cells through p53
activation (Vergoni et al., 2016). This way, a reduction in
the availability of adipocytes and stromal vascular cells by
doxorubicin could compromise gene transcription, which could
cause this discrepancy between Col6a3 and fibronectin mRNA
in comparison with the total fibrotic area. In agreement with
this, the co-incubation of MET an adipocyte culture treated with
doxorubicin resulted in an increase in cell viability (data not
shown).
CONCLUSION
The administration of MET concomitant with doxorubicin
treatment attenuated fibrosis and insulin resistance caused by
this chemotherapy drug in SAT. MET showed significant results,
which demonstrate the importance of new studies to clarify the
role of MET in the reduction of chemotherapy-related side effects
in relevant organs to metabolism control.
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